As per the research report, the size of the Asia Pacific Bleeding Disorders Treatment Market is valued at USD 2.62 billion in 2022 and is estimated to be growing at a CAGR of 8.90%, to reach USD 4.02 billion by 2027 during the forecast period 2022 to 2027.
The market is driven by the growing need for bleeding disorders drugs to meet critical medical requirements to limit blood loss and is one of the significant growth drivers in this market. Moreover, the unavailability of a definitive treatment plan of completely removing the disorder permanently from the patient's body is also influencing the market growth. In addition, there is a constant increase in the number of patients diagnosed with bleeding disorders, increased awareness of bleeding disorders, improved quickness, an extensive network of diagnostic and treatment centers, accurate diagnostic tests and proactive government initiatives are some of the essential factors helping in establishing this market.
Key companies are focusing on intensive research and development to provide more effective drugs to patients to reduce side-effects and help in the wide-spread adoption of these technologically advanced products in the APAC healthcare industry. There were around 730 million people over the age of 65 in 2020, and they represented 9.35% of the total world population. The senior population is analyzed to reach over 16.32% by 2050. This drives the APAC bleeding disorders treatment market with high renal disease, compromised immunity, and a host of other age-related diseases, which disturbs the bleeding and clotting time in the body.
According to the World Federation of Hemophilia, approximately one in 10,000 people are born with this disease. According to the WHO, about 1/3 of new diagnoses occur when there is no family history, majorly affecting the males. According to the Centers for Disease Control, nearly 2% of the population has hemophilia. In addition, according to the CDC, 93% of women with the disease have heavy menstrual bleeding. All these numbers are anticipated to increase in the future and will support the growth of the APAC bleeding disorders treatment market during the prognosis period.
Some of the main factor restraining this market the lack of access to adequate treatment due to the high cost of drugs, unavailability of skilled professionals and the scarcity of availability of specialized health services needed to treat these diseases. Limited healthcare resources will hamper the market growth in some underdeveloped and developing nations in APAC region. In addition, treatment with plasma-derived products may increase the risk of transmission of blood-borne infections like hepatitis and HIV.
This research report on the Asia Pacific Bleeding Disorders Treatment Market has been segmented and sub-segmented into the following categories:
By Drug Class:
Geographically, the Asia Pacific Bleeding Disorders Treatment Market is predicted to rise due to the high expenditure on healthcare facilities, and booming research and development facilities will increase the demand in this region.
The China Bleeding Disorders Treatment Market is analyzed to hold the largest share due to the presence of a large patient pool, the availability of skilled technicians at a comparatively lower cost, and a defined regulatory framework that promotes expedited approval of products.
The India Bleeding Disorders Treatment Market has the highest growth rate, attributed to developing healthcare infrastructure, growing patient awareness, increased public spending, and a large senior population in this region.
Moreover, the rapid increase in India is supporting the market growth and contributing to the overall APAC regional revenues.
KEY MARKET PLAYERS
The Top companies leading in the APAC Bleeding Disorders Treatment Market profiled in the report are CSL Behring, Pfizer Inc., Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Janssen Asia-Pacific Services, LLC, and Grifos SA.,